Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: a retrospective real-world study
In conclusion, cadonilimab combined with AG chemotherapy demonstrated promising antitumor activity and manageable safety in PDAC. Dynamic monitoring of PLR and CA19-9 may aid efficacy evaluation, but these exploratory findings require confirmation in prospective multicenter trials.
Authors
- Yongqing Zhao
- Wen Qin (ORCID: https://orcid.org/0000-0002-2714-3613)
- Yan Du (ORCID: https://orcid.org/0000-0001-9931-4197)
- Zengxi Yang
- Kongyuan Wei (ORCID: https://orcid.org/0000-0001-5288-642X)
- Xin Li (ORCID: https://orcid.org/0000-0002-8135-9482)
- Yan Zhang (ORCID: https://orcid.org/0000-0003-0244-218X)
- Jubao Niu
- Xuean Zhao
- Shuze Zhang
- Dewen Zhao
- Hui Zhang (ORCID: https://orcid.org/0000-0001-6300-9334)
Institutions
- Jining Traditional Chinese Medicine Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Lanzhou University Second Hospital (CN)
- First Hospital of Xi'an (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1654425
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China